Abstract
Abstract:
Osteoporosis is the most prevalent bone disease in the US. Once diagnosed, osteoporosis requires ongoing management; therefore, primary care providers are vital in managing both primary and secondary fracture prevention. Safe, efficacious, and economical medications are available, but osteoporosis remains underdiagnosed and undertreated. Bisphosphonates, selective estrogen receptor modulators (raloxifene), conjugated estrogens/bazedoxifene, estrogen therapy/hormone therapy, parathyroid hormone analogues, RANK ligand inhibitors (denosumab), sclerostin inhibitors (romosozumab), and calcitonin are all drugs or drug classes commonly used to treat osteoporosis that are discussed in this article.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference33 articles.
1. Medicare cost of osteoporotic fractures: the clinical and cost burden of an important consequence of osteoporosis;Hansen
2. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States;Lewiecki;JBMR Plus,2019
3. The clinician's guide to prevention and treatment of osteoporosis;LeBoff;Osteoporosis Int,2022
4. Osteoporosis: enhancing management in primary care;Bennett;Endocrinol Today,2022
5. Vertebrate mineralized matrix proteins: structure and function;Robey;Connect Tissue Res
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecular and Cellular Mechanisms of Osteoporosis;International Journal of Molecular Sciences;2023-10-30